RWPA
ABBV icon

Richard W. Paul & Associates’s AbbVie ABBV Stock Holding History

Richard W. Paul & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
7,599
+570
+8% +$123K 0.58% 41
2026
Q1 		$1.53M Buy
7,029
+133
+2% +$29.5K 0.51% 47
2025
Q4 		$1.58M Sell
6,896
-231
-3% -$52.6K 0.52% 44
2025
Q3 		$1.65M Sell
7,127
-245
-3% -$49.9K 0.56% 40
2025
Q2 		$1.37M Sell
7,372
-202
-3% -$37.5K 0.49% 45
2025
Q1 		$1.59M Sell
7,574
-179
-2% -$34.8K 0.62% 33
2024
Q4 		$1.38M Buy
7,753
+307
+4% +$56.4K 0.5% 49
2024
Q3 		$1.47M Sell
7,446
-146
-2% -$27.2K 0.53% 44
2024
Q2 		$1.3M Sell
7,592
-880
-10% -$146K 0.5% 46
2024
Q1 		$1.54M Sell
8,472
-302
-3% -$52K 0.62% 40
2023
Q4 		$1.36M Sell
8,774
-80
-0.9% -$11.7K 0.57% 44
2023
Q3 		$1.32M Sell
8,854
-1,203
-12% -$177K 0.6% 39
2023
Q2 		$1.35M Buy
10,057
+363
+4% +$53.2K 0.59% 46
2023
Q1 		$1.55M Sell
9,694
-89
-0.9% -$13.6K 0.71% 38
2022
Q4 		$1.58M Buy
+9,783
New +$1.5M 0.8% 32

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Richard W. Paul & Associates's ABBV Position: Q2 2026 in Review

Richard W. Paul & Associates increased its AbbVie (ABBV) stake by 8.1% in Q2 2026, buying an estimated $123K and bringing the position to 7,599 shares worth $1.91M. The position accounts for 0.58% of the portfolio, ranked #41.

Richard W. Paul & Associates first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Richard W. Paul & Associates held 7,599 shares of AbbVie worth $1.91M as of Q2 2026.
  • Richard W. Paul & Associates bought 570 AbbVie shares in Q2 2026, an estimated $123K.
  • AbbVie made up 0.58% of Richard W. Paul & Associates's portfolio in Q2 2026, its #41 holding.
  • Richard W. Paul & Associates first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Richard W. Paul & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.